Clinical Trial Update: A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on toripalimab with nab-paclitaxel with or without cisplatin as first-line treatment for urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Jun Guo | Conditions: Urothelial Carcinoma | Phase 2 | Status: UNKNOWN